AVEO Pharmaceuticals — Investor Presentation (August 2022)
44 slides from AVEO Pharmaceuticals's investor presentation, Aug 9, 2022
Slide 1: Corporate Overview August 2022
Passionately pursuing a better life for patients with cancer Corporate Overview August 2022
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained
Slide 3: Oncology Company With Pipeline to Drive Long-term Growth
Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner VEGFR TKI Ficlatuzumab Anti-HGF/c-MET IgG1 mAb AV-380 Anti-GDF15 IgG1 mAb AV-203 Anti-ERBB3 IgG1 mAb AV-353 Anti-Notch 3 IgG1 mAb Oncology Company With Pipeline to Drive Long-term Growth Ex-US (RCC 1st line) US (RCC following two
Slide 4: Oncology
ONCOLOGY ()FOTIVDA M/=O (tivozanio) capsules
Slide 5: FOTIVDA (tivozanib)
Full prescribing information available at www.FOTIVDA.com FOTIVDA® (tivozanib) FOTIVDA (tivozanib) is an oral, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (
Slide 6: FOTIVDA: A Uniquely Positioned VEGF-TKI
FOTIVDA: A Uniquely Positioned VEGF-TKI • Potent, selective, long half-life inhibitor of all three VEGF receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities • TIVO-3: Superior disease control (PFS, ORR & DoR) vs. sorafenib • Fewer dose reductions, interruptions
Slide 7: ASCO 2022 – Five Year Efficacy Update
7 ASCO 2022 – 5 Year Efficacy Update • Five year follow-up data show FOTIVDA® (tivozanib) patients were up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) and a trend toward improved Overall Survival (OS) HR=0.89 • When OS was conditioned on 12 months of PFS, an improv
Slide 8: Significant Unmet Need In R/R Advanced RCC
Significant Unmet Need In R/R Advanced RCC1 Limited data exists for the treatment of highly refractory RCC patients and following immunotherapy Existing treatment options have tolerability challenges requiring frequent dose modifications Only about 50% of patients who received second-line treatment
Slide 9: IMDC Database: Third-line Treatment Demonstrated to Improve Survival
0.00 0.25 0.50 0.75 1.00 0 20 40 60 80 100 IMDC Database: Third-line Treatment Demonstrated to Improve Survival ~2X vs. No Therapy1 9 ** 1 Wells JC, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consorti
Slide 10: US RCC Market by Line of Therapy
US RCC Market by Line of Therapy 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 1st Line 2nd Line 3rd Line+ Annual Incidence of RCC Patients by Line of Therapy1 Treated Un-Treated 1) Decision Resources Group (DRG) projections 2022 (Nov. 2021 Market Update) • 10,000 patients make it to
Slide 11: Quarter over Quarter Prescription Growth
0 283 619 780 977 1,157 Q1 '21* Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 T o ta l P re s c ri p ti o n V o lu m e Quarter over Quarter Prescription Growth Q2 ‘22 Notes • 18% growth in TRxs from Q1 ’22 to Q2 ’22 • 309% growth in TRxs over Q2 ’21 • Increasing in-person access and activity *Commercial Availa
Slide 12: FOTIVDA U.S. Net Product Revenue by Quarter
FOTIVDA® U.S. Net Product Revenue by Quarter $6.7 $14.3 $16.8 $20.1 $25.0 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 (I n M il li o n s ) Q2 ‘22 Notes • 24% growth in U.S. Net Product Revenue from Q1 ’22 to Q2 ’22 • 271% growth in U.S. Net Product Revenue over Q2 ’21 • Reaffirm guidance of $100-110m in ’22
Slide 13: Impact of NCCN Guideline Update on Decision Making
Nearly 80% of respondents indicated that the recent NCCN Guideline update elevating tivozanib to a Category 1 recommendation was significantly or moderately impactful on their treatment decisions, in a recent third party market research survey 9% 12% 40% 39% 0 20 40 60 80 100 No impact Low impact Mo
Slide 14: Improving 3rd Line+ Duration of Therapy
Improving 3rd Line+ Duration of Therapy • Longitudinal data available for approximately 250 real world patients initiating treatment in Q2 through Q4 2021 (Minimum of 6 months follow up) • Average duration is currently 4.7 months with 21% continuing active treatment 0 1 2 3 4 5 21% Still Ongoing Lon
Slide 15: Focused Oncology Team with Broad Market Coverage
Focused Oncology Team with Broad Market Coverage • Experienced oncology field force for effective market coverage (~65 FTEs) • Commercial Team designed for success through evolving COVID restrictions • Full in-person and remote customer engage capabilities • Multi-channel promotional initiatives • A
Slide 16: Best-in-Class Patient Access Services
Best-in-Class Patient Access Services • FOTIVDA® (tivozanib) Is Available Through a Limited Network of Specialty Pharmacies and Distributors • Limited distribution model through high-touch specialty pharmacies and top specialty distributors supports in-office dispensing practices. • Unique model in
Slide 17: FOTIVDA Recognized As Overperforming First Launch
FOTIVDA Recognized As Overperforming First Launch *https://www.zs.com/insights/us-emerging-pharma-biotech-first-launch-analysis
Slide 18: Tivozanib Combination Opportunities
Tivozanib Combination Opportunities
Slide 19: Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy
Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Unique Advantages in Combination with CPI Therapy 19 Tolerability is Important in Combinations Tivozanib Significantly Reduce
Slide 20: Anti-tumor Activity Seen in Treatment Naive and Previously Treated RCC Patients
Treatment Naïve (n=12) Pre-Treated (n=13) Includes 2 Prior CPI Pts Overall (n=25) CR 8% - 4% PR 42% 62% 52% ORR (CR+PR) 50% 62% 56% DCR (CR+PR+SD) 92% 100% 96% mPFS 18.9 mo (4.7, NR) NR* (11.0, NR) 18.9 mo (16.4, NR) Dose reductions 17% Nivolumab Mono2Tivozanib Mono1 ORR 18% PFS 11.0 ORR 25% PFS 4.6
Slide 21: TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy
TiNivo-2: Pivotal Trial in RCC Following Prior Immunotherapy Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare FOTIVDA® with OPDIVO® to FOTIVDA® in RCC Patients Following One or Two Lines of Therapy, One of which was an Immune Checkpoint Inhibitor N = 326 • Histologically /
Slide 22: 1st Line HCC VEGF Combination Comparison
Regimen Study PS Status ECOG 0 ORR^ DCR PFS* 1 Year OS Rate Bev+Atezo1, 2 Ph3 N=501 (2:1) 62% 28% 74% 6.8m 67% Cabo+Atezo3 Ph3 N=372 (2:1) 64% 11% 78% 5.8m N/A Tivo+Durva4 Ph2 N=18 40% 28% 72% 7.3m 76% References: 1USPI for Tecentriq; 2Verret, W. et al., Atezolizumab plus Bevacizumab in Unresectable
Slide 23: Clinical Trial Collaboration: Tivozanib and NKT2152
Clinical Trial Collaboration: Tivozanib and NKT2152 • AVEO and NiKang entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang’s small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with tivozanib • Sixty patient Phase 2 clinical trial
Slide 24: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb
Ficlatuzumab Anti-HGF/c-MET IgG1 mAb
Slide 25: Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC
Scientific Rationale for Ficlatuzumab in Combination with Cetuximab for HPV-negative HNSCC 25 Source: Zhang Y, Jain R and Zhu M. Biomedicines, 2015 (Zhang Y, Jain RK, and Zhu M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines. 2015; 3, 149-181 d
Slide 26: Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC
Potential Ficlatuzumab Registrational Trial in HPV Negative HNSCC Update • Granted U.S. FDA Fast Track Designation for the treatment of patients with R/R HNSCC • Completed drug substance manufacturing for potential registrational study of ficlatuzumab in 2Q 2022 • Potential registrational trial star
Slide 27: Financials and Near-Term Milestones
Financials and Near-Term Milestones
Slide 28: Financial Snapshot as of June 30, 2022
28 Cash as of June 30, 2022 $77.2M Total U.S. Net Product Revenue 2Q 2022 $25.0M Debt as of June 30, 2022 $38.4M Shares Outstanding as of June 30, 2022 34.6M 2Q 2022 1H 2022 Cash Burn from Operations ($1.9M) ($10.2M) AVEO believes that its current cash, cash equivalents and marketable securities, al
Slide 29: Key Recent and Potential Milestones
Key Recent and Potential Milestones AV-380 (Anti-GDF15 IgG1 mAb) 2021 1H 22 2H 22 Initiate Phase 1b Trial in Cancer Patients with Elevated GDF15 Levels Who Have the Potential to Develop Cachexia Ficlatuzumab (Anti-HGF/c-MET IgG1 mAb) 2021 1H 22 2H 22 HNSCC Randomized (Ficlatuzumab +/- Cetuximab) Pha
Slide 30: Thank you
Passionately pursuing a better life for patients with cancer Thank you
Slide 31: Appendix
Appendix A/=O ONCOLOGY
Slide 32: FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI
FOTIVDA: A Differentiated VEGFR 1, 2 and 3 TKI Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life designed to improve efficacy and tolerability 32 Pawlowski N et al. AACR 2013. Poster 3971. • Cabozantinib and lenvatinib are not shown because absolute oral bioavailabilities are no
Slide 33: TIVO-3: Pivotal Trial in RCC
: Pivotal Trial in RCC Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects With R/R Advanced RCC Results published in Lancet Oncology in December 2019 N = 350 • Histologically / cytologically confirmed recurrent/metastatic RCC • ECOG PS 0 or
Slide 34: TIVO-3: First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies
: First Positive Phase 3 Dataset in Adult Patients Receiving Two or More Prior Systemic Therapies Source: PFS final analysis, Oct 4, 2018, U.S. FOTIVDA® Package Insert34 TIVO-3 Primary Endpoint: PFS of Tivozanib vs. Sorafenib Secondary Endpoints: ORR, DCR, DoR, OS Treatment Group Tivozanib n=175 Sor
Slide 35: TIVO-3: Exploratory Analysis of Pre-Defined Subgroups
: Exploratory Analysis of Pre-Defined Subgroups: Prior Checkpoint Inhibitor and TKI/TKI 35 Porta et al. ASCO 2019 Other + VEGFR TKI: (N=100) HR=0.98; 95% CI 0.62; 1.56, ASCO GI 2019 0 20 40 60 80 100 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 P ro g re s s io n -f re e S u rv iv a l (% ) 0 20 40 60
Slide 36: TIVO-3: Safety & Tolerability
*Analysis as of Aug 15, 2019; ^Safety population **Includes fatigue and asthenia; † Includes hypertension, blood pressure increased, hypertensive crisis; § Includes diarrhea and frequent bowel movements.; # Includes dermatitis, dermatitis acneiform, dermatitis contact, drug eruption, eczema, eczema
Slide 37: Ficlatuzumab Anti-HGF/c-MET IgG1 mAb
Ficlatuzumab Anti-HGF/c-MET IgG1 mAb
Slide 38: Ficlatuzumab: Phase 2 Randomized Study in Pan-Refractory, Metastatic HNSCC Patients
Ficlatuzumab: Phase 2 Randomized Study in Pan- Refractory, Metastatic HNSCC Patients Randomized, confirmatory Phase 2 study in combination with cetuximab, an EGFR-targeted antibody, patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab with metastatic HNSCC N =
Slide 39: Efficacy Benchmarks: Low Response Rates and Limited PFS in R/M HNSCC
FDA Approved Nov 20162,3 Ph3 n=361 OPDIVO (nivolumab) vs Investigator Choice ORR 13% vs 5.8% 2.0m vs 2.3m PFS 1ERBITUX (cetuximab) USPI November 2020, Eli Lilly and Company, Indianapolis, IN. 2OPDIVO (nivolumab) USPI January 2021, Bristol Myers Squibb, Princeton, NJ., 3http://www.fda.gov/Drugs/Infor
Slide 40: Significant Unmet Need Exists for HPV Negative HNSCC
Significant Unmet Need Exists for HPV Negative HNSCC1 40 1 Galvis et al, Critical Reviews in Oncology/Hematology 15 (2020) 102966
Slide 41: Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative HNSCC
41 Ficlatuzumab Plus Cetuximab Improved Outcomes in HPV Negative Pan-Refractory, Metastatic HNSCC HPV negative HNSCC is historically associated with poorer outcomes compared to HPV positive disease F (=26) F+C (n=32) HPV+ ORRa 0/10 (0%) 0/16 (0%)d mPFSb NEc 2.3 (1.9)e HPV- ORRa 1PR/16 (6%) 2CR + 4PR
Slide 42: Additional Pipeline Programs
Additional Pipeline Programs
Slide 43: AV-380: GDF15 Role in Cachexia
AV-380: GDF15 Role in Cachexia 43 * J. Cachexia, Sarcopenia and Muscle 2010 + AVEO data on file Cachexia is a muscle wasting disease commonly associated with cancer • ~50% of people with cancer will suffer from cachexia* • ~30% of all cancer patients die from cachexia* GDF15 is a key driver in cance
Slide 44: AV-203: A potent humanized IgG1 mAb that targets ErbB3
AV-203: A potent humanized IgG1 mAb that targets ErbB3 • Humanized IgG1 antibody – Low risk of ADA response and hypersensitivity – Potential for inducing ADCC • Potent inhibitor of NRG/HRG - dependent and independent ERBB3 activation • Higher ERBB3 affinity and more potent anti-tumor activity than c
AVEO Pharmaceuticals — Investor Presentation (August 2022) on 6ix